KNSA PE Ratio & Valuation,Is KNSA Overvalued

KNSA Relative Valuation

KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KNSA is overvalued; if below, it's undervalued.

Historical Valuation

Kiniksa Pharmaceuticals International PLC (KNSA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -289.44. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：41.55

Fair

27.54

19.90

EV/EBITDA

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBITDA of 19.90. The 5-year average EV/EBITDA is -26.66. The thresholds are as follows: Strongly Undervalued below -326.73, Undervalued between -326.73 and -176.69, Fairly Valued between 123.38 and -176.69, Overvalued between 123.38 and 273.42, and Strongly Overvalued above 273.42. The current Forward EV/EBITDA of 19.90 falls within the Historic Trend Line -Fairly Valued range.

20.20

EV/EBIT

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current EV/EBIT of 20.20. The 5-year average EV/EBIT is 1.28. The thresholds are as follows: Strongly Undervalued below -76.15, Undervalued between -76.15 and -37.43, Fairly Valued between 40.00 and -37.43, Overvalued between 40.00 and 78.72, and Strongly Overvalued above 78.72. The current Forward EV/EBIT of 20.20 falls within the Historic Trend Line -Fairly Valued range.

3.74

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current PS of 3.74. The 5-year average PS is 9.78. The thresholds are as follows: Strongly Undervalued below -45.67, Undervalued between -45.67 and -17.95, Fairly Valued between 37.51 and -17.95, Overvalued between 37.51 and 65.23, and Strongly Overvalued above 65.23. The current Forward PS of 3.74 falls within the Historic Trend Line -Fairly Valued range.

-67.79

P/OCF

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/OCF of -67.79. The 5-year average P/OCF is 195.10. The thresholds are as follows: Strongly Undervalued below -1875.79, Undervalued between -1875.79 and -840.34, Fairly Valued between 1230.54 and -840.34, Overvalued between 1230.54 and 2265.99, and Strongly Overvalued above 2265.99. The current Forward P/OCF of -67.79 falls within the Historic Trend Line -Fairly Valued range.

46.82

P/FCF

Kiniksa Pharmaceuticals International PLC. (KNSA) has a current P/FCF of 46.82. The 5-year average P/FCF is -32.57. The thresholds are as follows: Strongly Undervalued below -359.38, Undervalued between -359.38 and -195.97, Fairly Valued between 130.84 and -195.97, Overvalued between 130.84 and 294.25, and Strongly Overvalued above 294.25. The current Forward P/FCF of 46.82 falls within the Historic Trend Line -Fairly Valued range.

Kiniksa Pharmaceuticals International PLC (KNSA) has a current Price-to-Book (P/B) ratio of 5.86. Compared to its 3-year average P/B ratio of 3.47 , the current P/B ratio is approximately 68.85% higher. Relative to its 5-year average P/B ratio of 3.67, the current P/B ratio is about 59.51% higher. Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.86%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.42% , the current FCF yield is about -100.00% lower.

5.86

P/B

Median3y

3.47

Median5y

3.67

3.23

FCF Yield

Median3y

1.86

Median5y

-4.42

Competitors Valuation Multiple

The average P/S ratio for KNSA's competitors is , providing a benchmark for relative valuation. Kiniksa Pharmaceuticals International PLC Corp (KNSA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 61.17%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of KNSA increased by 110.06% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 26.28 to 89.08.

The secondary factor is the Revenue Growth, contributed 61.17%to the performance.

Overall, the performance of KNSA in the past 1 year is driven by P/E Change. Which is more unsustainable.

61.17%

112.21M → 180.86M

Revenue Growth

-190.10%

-11.31 → 10.19

Margin Expansion

238.99%

26.28 → 89.08

P/E Change

110.06%

19.78 → 41.55

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Kiniksa Pharmaceuticals International PLC (KNSA) currently overvalued or undervalued?

What is Kiniksa Pharmaceuticals International PLC (KNSA) fair value?

KNSA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kiniksa Pharmaceuticals International PLC (KNSA) is between NaN to NaN according to relative valuation methord.

How does KNSA's valuation metrics compare to the industry average?

What is the current P/B ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 16 2025?

As of Dec 16 2025, Kiniksa Pharmaceuticals International PLC (KNSA) has a P/B ratio of 5.86. This indicates that the market values KNSA at 5.86 times its book value.

What is the current FCF Yield for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 16 2025?

As of Dec 16 2025, Kiniksa Pharmaceuticals International PLC (KNSA) has a FCF Yield of 0.00%. This means that for every dollar of Kiniksa Pharmaceuticals International PLC’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 16 2025?

As of Dec 16 2025, Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward P/E ratio of 27.54. This means the market is willing to pay $27.54 for every dollar of Kiniksa Pharmaceuticals International PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Kiniksa Pharmaceuticals International PLC (KNSA) as of Dec 16 2025?

As of Dec 16 2025, Kiniksa Pharmaceuticals International PLC (KNSA) has a Forward P/S ratio of 0.00. This means the market is valuing KNSA at $0.00 for every dollar of expected revenue over the next 12 months.

KNSA Valuation